modelJ05AF09
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Emtricitabine | |
| ATC code: | J05AF09 | route: | oral |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 1.23 | L |
| clearance: | 25.3 | L/h |
| other parameters in model implementation | ||
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) used as an antiretroviral drug in the treatment and prevention of HIV-1 infection. It is often used in combination with other antiretrovirals and is approved for clinical use worldwide.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult individuals after oral administration of 200 mg emtricitabine.
References
Valade, E, et al., & Hirt, D (2014). Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. Antimicrobial agents and chemotherapy 58(4) 2256–2261. DOI:10.1128/AAC.02058-13 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24492366
Dickinson, L, et al., & Boffito, M (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. The Journal of antimicrobial chemotherapy 75(3) 628–639. DOI:10.1093/jac/dkz479 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31754703
Néant, N, et al., & Solas, C (2018). Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. European journal of clinical pharmacology 74(4) 473–481. DOI:10.1007/s00228-017-2405-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29374296
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)